Suppression of Dexamethasone-induced Metallothionein Expression and as-Diamminedichloroplatinum(II) Resistance by V-mos

Cancer Research

Volumn 51, Issue 3, 1991, Pages 893-896

  Lazo, John S ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; METALLOTHIONEIN;

ANIMAL CELL; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG RESISTANCE; GENE EXPRESSION; KIDNEY CELL; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; RAT;

ANIMAL; CELL TRANSFORMATION, NEOPLASTIC; DEXAMETHASONE; DRUG RESISTANCE; KIDNEY; METALLOTHIONEIN; ONCOGENE PROTEINS V-MOS; ORGANOPLATINUM COMPOUNDS; RATS; RETROVIRIDAE PROTEINS, ONCOGENIC; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025972913     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hamer, D. Metallolhionein. Annu. Rev. Biochem., 55: 913-951. 1986.
2. Kagi, J. H. R., and Schaffer, A. Biochemistry of metallothionein. Biochemistry, 27: 8509-8515, 1988.
3. Nartely, N. O., Banerjee, D., and Cherian, M. G. Immunohistochemical localization of metallothionein in cell nucleus and cytoplasm of fetal human liver and its changes during development. Pathology, 49: 233-238. 1987.
4. Nartely, N., Cherian, M. G., and Banerjee, D. Immunohistochemical local ization of metallothionein in human thyroid tumors. Am. J. Pathol., 129: 177-182, 1987.
5. Karin, M. Metallothioneins: proteins in search of function. Cell, 41: 9-10, 1985.
6. Bakka, A., Endresen, I., Johnsen, A. B. S., Edminson, P. D., and Rugstad, H. E. Resistance against cis-dichlorodiammineplatinum in cultured cells with a high content of metallothionein. Toxicol. Appi. Pharmacol., 61: 215-226, 1981.
7. Kelly, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H., and Lazo, J. S. Overexpression of metallothionein confers resistance to anticancer drugs. Science (Washington DC), 214: 1813-1815, 1988.
8. Loher, H., and Robson, T. Overexpression of metallothionein in CHO cells and its effect on cell killing by ionizing radiation and alkylating agents. Carcinogenesis (Lond.), 10: 2279-2284, 1989.
9. Basu, A., and Lazo, J. S. A hypothesis regarding the protective role of metallothioneins against the toxicity of DNA interactive anticancer drugs. Toxicol. Lett., 50:123-135, 1990.
10. Schilder, R. J., Hall, L., Monks, A., Handel, L. M., Fornace, A. J., Ozols, R. F., Fojo, A. T., and Hamilton, T. C. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int. J. Cancer, 45:416-422, 1990.
11. Alonso, T., Moegan, R. O., Marvizon, J. C., Zarbl, H., and Santos, E. Malignant transformation by ras and other oncogenes produces common alterations in inositol phospholipid signaling pathways. Proc. Natl. Acad. Sci. USA, 85:4271-4275, 1988.
12. Jaggi, R., Hock, W., Ziemiecki, A., Klemenz, R., Friis, R., and Groner, B. Oncogene mediated repression of glucocorticoid hormone response elements and glucocorticoid receptor levels. Cancer Res., 49: 2266s-2274s, 1989.
13. Greenberger, J. S., Davisson, P. B., and Gans, P. J. Murine sarcoma viruses block corticosteroid-induced differentiation of bone marrow preadipocytes associated with long-term in vitro hemopoiesis. Virology, 95:317-333,1979.
14. Hamilton, B. J., and DeFranco, D. Glucocorticoid and cAMP induction mechanisms are differentially affected by the p85sos-mos oncoprotein. Proc. Natl. Acad. Sci. USA, 86: 597-601, 1989.
15. Cizdziel, P. E., Nash, M. A., Blair, D. G., and Murphy, E. C., Jr. Molecular basis underlying phenotypic revenants of Moloney murine sarcoma virus MuSVtsl 10. J. Virol., 57: 310-317, 1986.
16. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D., and Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetrie assay: assessment of chemosensitivity testing. Cancer Res., 47:936-942, 1987.
17. Markman, M., Scheidler, V., Ettinger, D. S., Quaskey, S. A., and Mellits, E. D. Antiemetic efficacy of dexamethasone: randomized double-blind, cross over study with prochlorperazine in patients receiving cancer chemotherapy. N. Engl. J. Med. 311: 549-552, 1984.
18. Krezoski, S. K., Villalobos, J., Shaw, C. F., and Petering, D. H. Kinetic lability of zinc bound to metallothionein in Ehrlich cells. Biochem. J., 255: 483-491, 1988.
19. Levi, F. A., Hrushesky, W. J. M., Blomquist, C. H., Lakatua, D. J., Haus, E., Halberg, F., and Kennedy, B. J. Reduction of m-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res., 42: 950-955, 1982.
20. Qi, M., Hamilton, B. J., and DeFranco, D. V-mos oncoproteins affect the nuclear retention and reutilization of glucocorticoid receptors. Mol. Indo crinol., 5:1279-1288, 1989.
21. Qi, M., Stasenko, L. J., and DeFranco, D. B. Recycling and desensitization of glucocorticoid receptors in V-mos transformed cells depend on the ability of nuclear receptors to modulate gene expression. Mol. Endocrinol., 4:455-464, 1990.
22. Aapro, M. S., Alberts, D. S., and Serokman, R. Lack of dexamethasone effect on the antitumor activity of cisplatin. Cancer Treat Rep., 67: 1013-1017, 1983.